SUPN Share Price

Open 43.85 Change Price %
High 43.85 1 Day -2.25 -5.10
Low 41.51 1 Week -0.90 -2.11
Close 41.85 1 Month 6.10 17.06
Volume 732990 1 Year 22.79 119.57
52 Week High 44.95
52 Week Low 17.25
SUPN Important Levels
Resistance 2 44.02
Resistance 1 43.13
Pivot 42.40
Support 1 40.57
Support 2 39.68
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.22 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
QQQ 138.03 -1.81%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SMSI 1.62 24.62%
CGEI 0.22 22.22%
THTI 0.20 17.65%
MYRX 0.07 16.67%
BDMS 13.50 16.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

SUPN Technical Analysis 5
As on 27th Jun 2017 SUPN Share Price closed @ 41.85 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 27.00 & Strong Buy for SHORT-TERM with Stoploss of 35.63 we also expect STOCK to react on Following IMPORTANT LEVELS.
SUPN Target for June
1st Target up-side 42.31
2nd Target up-side 45.62
3rd Target up-side 48.92
1st Target down-side 32.89
2nd Target down-side 29.58
3rd Target down-side 26.28
SUPN Other Details
Segment EQ
Market Capital 306384160.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.supernus.com
SUPN Address
SUPN
1550 East Gude Drive
Rockville, MD 20850
United States
Phone: 301-838-2500
Interactive Technical Analysis Chart Supernus Pharmaceuticals, Inc. ( SUPN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Supernus Pharmaceuticals, Inc.
SUPN Business Profile
Supernus Pharmaceuticals, Inc. (Supernus) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�s two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.